UV Flu Technologies appoints board member
Glenn Bushee joins the air quality specialist which is nearing launch of UV-400 air purifier
For a number of years, Bushee lived in China to oversee all facets of production and formed a network of industry contacts and familiarity with several manufacturing concerns of significant interest to UV Flu. While he was president of 3P North America, for example, Bushee designed and sold Comfort Mist UV air purifiers, which sold almost US$20m of product annually.
UV Flu says it anticipates commercial availability of the updated ViraTech UV-400 shortly. The latest production run of the air purifier combines patented UV bacteria killing technology, which has been cleared by the US FDA for use as a medical device, with a newly developed catalytic UV technology, and also incorporates an activated carbon screen.
“We believe the UV-400, with these new product improvements combined with its patented UV technology, is the most effective, bacteria-killing air purifier in the world today,” said Jack Lennon, president of UV Flu Technologies.
“We have worked diligently with our engineers in China to improve the effectiveness of our product, and provide even more value for our customers. We are getting requests for information on a daily basis from countries all over the world, particularly from hospitals.”
You may also like
Design & Build
SRBA Controlled Environments and ABN Cleanroom Technology join forces on 3D printing cleanroom
Contracting SRBA Controlled Environments and ABN Cleanroom Technology, KMWE has completed a cleanroom project at the Brainport Industries Campus in the Netherlands 3D printing and repair facility
Sustainability
First annual Microngreen Report: Turning words into results
Micronclean is proud to announce the publication of its first annual Microngreen Report, which highlights its progress towards becoming "the most sustainable specialist textile and cleanroom consumable business on the planet."
Design & Build
Drive for innovation: New biologicals development centre of Boehringer Ingelheim
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, is dedicated to advancing innovation in areas with significant medical needs. With its primary research and development centre based in Biberach, the company employs approximately 7,500 individuals who are focused on creating human pharma, as well as animal health products